Personalis (NASDAQ:PSNL) Shares Gap Up – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) shares gapped up prior to trading on Tuesday . The stock had previously closed at $7.83, but opened at $8.53. Personalis shares last traded at $8.57, with a volume of 487,482 shares changing hands.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several analyst reports. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. HC Wainwright lifted their target price on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Guggenheim upped their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research reissued a “buy” rating and set a $12.00 price objective on shares of Personalis in a research report on Friday, January 9th. Finally, Morgan Stanley upped their target price on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.71.

Personalis Price Performance

The firm has a market cap of $767.23 million, a PE ratio of -9.84 and a beta of 1.98. The company’s 50 day moving average price is $8.97 and its 200 day moving average price is $7.67.

Insiders Place Their Bets

In related news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Personalis

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its stake in shares of Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares during the period. Goldman Sachs Group Inc. increased its position in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares during the period. Focus Partners Wealth acquired a new position in Personalis during the first quarter worth $47,000. Finally, Aberdeen Group plc grew its stake in shares of Personalis by 3.2% during the 2nd quarter. Aberdeen Group plc now owns 1,759,497 shares of the company’s stock worth $11,542,000 after purchasing an additional 54,713 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.